More from the Author

• Teaching Note | HBS Case Collection | August 2020

  People Analytics at McKinsey

  Jeffrey T. Polzer and Olivia Hull

  Teaching note to accompany People Analytics at McKinsey, HBS No. 418-023.

  Keywords: people analytics; analytics; human resource management; business analytics;

  Citation:

  Polzer, Jeffrey T., and Olivia Hull. "People Analytics at McKinsey." Harvard Business School Teaching Note 421-022, August 2020.  View Details

  CiteView DetailsPurchase

  Related

• Working Paper | HBS Working Paper Series | 2020

  Collaborating During Coronavirus: The Impact of COVID-19 on the Nature of Work

  Evan DeFilippis, Stephen Michael Impink, Madison Singell, Jeffrey T. Polzer and Raffaella Sadun

  We explore the impact of COVID-19 on employee's digital communication patterns through an event study of lockdowns in 16 large metropolitan areas in North America, Europe and the Middle East. Using de-identified, aggregated meeting and email meta-data from 3,143,270 users, we find, compared to pre-pandemic levels, increases in the number of meetings per person (+12.9 percent) and the number of attendees per meeting (+13.5 percent), but decreases in the average length of meetings (-20.1 percent). Collectively, the net effect is that people spent less time in meetings per day (-11.5 percent) in the post-lockdown period. We also find significant and durable increases in length of the average workday (+8.2 percent, or +48.5 minutes), along with short-term increases in email activity. These findings provide insight from a novel dataset into how the nature of work has changed for a large sample of knowledge workers. We discuss these changes in light of the ongoing challenges faced by organizations and workers struggling to adapt and perform in the face of a global pandemic.

  Keywords: nature of work; collaboration; COVID-19; Organizations; Communication; Health Pandemics; North and Central America; Europe; Middle East;

  Citation:

  DeFilippis, Evan, Stephen Michael Impink, Madison Singell, Jeffrey T. Polzer, and Raffaella Sadun. "Collaborating During Coronavirus: The Impact of COVID-19 on the Nature of Work." Harvard Business School Working Paper, No. 21-006, July 2020.  View Details

  CiteView DetailsSSRN

  Related

• Case | HBS Case Collection | June 2020

  Breakthroughs at Blueprint Medicines

  Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

  Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development engine. Blueprint’s drug development strategy was twofold—it focused on creating a single drug compound for multiple disease indications, while at the same time developing drugs to track a disease through its progression. The company’s goal was to become a fully integrated biopharmaceutical company that could move from drug discovery to development to marketing. But it was increasingly challenging to prioritize and manage programs, personnel and partnerships.

  Keywords: precision medicine; cancer; biotechnology; drug development; Strategy; Expansion; Science; Genetics; Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts;

  Citation:

  Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.  View Details

  CiteView DetailsEducatorsPurchase

  Related